Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (October 2024)
36 slides from Sutro Biopharma's investor presentation, October 2024
Slide 1: Science Designed to Provide Endless Possibility
Science Designed to Provide Endless Possibility October 2024 Sutro Biopharma NASDAQ: STRO 1 NON CONFIDENTIAL
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than sta
Slide 3: Next-Generation ADCs and Biologics, Transforming Science for Patients
3 Next-Generation ADCs and Biologics, Transforming Science for Patients Luvelta Luvelta pipeline-in-a-drug potential with two registrational trials ongoing and multiple follow-on opportunities Proven Cell Free Discovery and Manufacturing Pipeline Platform Driving Three Emerging pipeline of next-gene
Slide 4: Sutro Pipeline Drives Broad Potential with Multiple Near-Term Catalysts
Sutro Pipeline Drives Broad Potential with Multiple Near-Term Catalysts Luvelta FRα-targeting ADC with Two Complementary Additional Luvelta Opportunities and Registrational Trials Next-Generation ADC Pipeline Ovarian Cancer (Fast Track Designation) Luvelta for Non-Small Cell Lung Cancer • Registrati
Slide 5: Partnerships Provide up to ~$3 Billion Potential Future Milestones plus Royalties
5 Partnerships Provide up to ~$3 Billion Potential Future Milestones plus Royalties Phase 2/3 vaccines Blackstone purchase of Phase 1 IL-2 cytokine STRO-003 (ROR1 ADC) Preclinical Exclusive license to for invasive 4% royalties on potential derivative for cancer preclinical program for immunostimulat
Slide 6: STRO-002 Luveltamab Tazevibulin (Luvelta)
STRO-002 Luveltamab Tazevibulin (Luvelta) 6 NON CONFIDENTIAL
Slide 7: Luvelta: Deliberate Design + Development Enables Pipeline-in-a-Drug Opportunity
Luvelta: Deliberate Design + Development Enables Pipeline-in-a-Drug Opportunity Precisely Designed ADC to Expand Potential to Address Multiple FRα Expressing Cancers, Patient Access Including those with Low Expression Levels Hemiasterlin payload • Promising clinical activity in all indications evalu
Slide 8: Significant Opportunities, Initially in Ovarian and Expanding to Additional FRα Expressing Cancers
Significant Opportunities, Initially in Ovarian and Expanding to Additional FRα Expressing Cancers Luvelta Potentially Doubles the Estimated Annual Incidence in FRα-Expressing Patient Populations Addressable PROC Patients (U.S., Europe and Japan) Percent of Ovarian Cancer Patients Eligible for Thera
Slide 9: Opportunity to be First Therapy for Broad PROC Patient Population
Opportunity to be First Therapy for Broad PROC Patient Population Treatment Eligibility is Driven Comparison of Potential Luvelta Population by FRα Biomarker Test with Approved ADC Population Luvelta has demonstrated clinical activity in PROC patients TPS Staining Intensity 1+ Staining Intensity 2+
Slide 10: Registrational Strategy Supported by Clinical Data from ~100 Patients
Registrational Strategy Supported by Clinical Data from ~100 Patients Maximum Reduction in Tumor Target Lesions in RECIST-Evaluable Patients (N=92 Evaluable) 20% 3 in 5.2, 2 in 4.3, 2 in <=2.9, and 1 in >=5.6mg/kg -30% Partial response Ovarian Cancer Patients Total (N = 99) Platinum Sensitive 21 (21
Slide 11: Prophylactic G-CSF with Higher 5.2mg/kg Dose Reduced Neutropenia
Use of Prophylactic G-CSF on Day 8 with Higher 5.2mg/kg Dose Demonstrated Effective Reduction of Neutropenia Maximum Reduction in Tumor Grade 3+ Neutropenia Cohort A1 vs. Cohort with G-CSF2 Target Lesions (N=16) 20% Cycle 1 Cycle 1+2 100% 80% 71.4% 66.7% Percent Patients 60% 73.7% -30% 90.6% Reducti
Slide 12: REFRαME-O1: Registration-directed Study for patients with PROC
REFRαME-O1: Registration-directed Study for patients with PROC • Part 1 – Fully enrolled (50 patients) in April 2024; patients now in follow up • Part 2 – Trial Open and Enrolling patients Phase 2: Phase 3: Eligibility Key Endpoints Dose Finding Randomized Trial • Platinum Resistant Ovarian Dose A:
Slide 13: REFRαME-P1: Addressing Unmet Patient Need + Accelerating PROC
REFRαME-P1: Addressing Unmet Patient Need + Accelerating PROC • Pediatric RAM AML – devastating disease impacting infants and toddlers: overall survival of 15-30% • Regulatory submission requirements in U.S. and Europe may be applicable for PROC submissions • Potential to receive priority review vou
Slide 14: Luvelta Plus Bevacizumab Combination Potentially Supports All-Comers Approach
Luvelta Plus Bevacizumab Combination Potentially Supports All-Comers Approach Phase 1b Response Data (Presented at ESMO 2024) 1 Phase 2 Expansion Cohort All Patients 4.3kg/mg Prior Bev FRαTPS • 23 patients enrolled to-date, (all doses) N=9 Naïve Treated <25% ≥25% including PSOC & PROC N=17 N=8 N=9 N
Slide 15: Luvelta Activity in Lower and/or Variable FRα Expression Tumors
Luvelta Demonstrated Compelling Anti-Tumor Activity and Manageable Safety Profile In Lower and/or Variable FRα Expression Tumors Endometrial RAM AML1 NSCLC N = 17 N = 25 Preclinical Evidence of anti-tumor activity Meaningful clinical responses, including complete Single dose and combination with PD-
Slide 16: FRα is Broadly Expressed Across Multiple Indications
16 mRNA expression level (RMA, log2) 6 4 8 10 12 endometrium (27) ovary (51) kidney (34) bile duct (8) colorectal (61) breast (58) pancreas (44) stomach (38) esophagus (25) lung_NSC (131) other (15) upper_aerodigestive (32) urinary tract (27) chondrosarcoma (4) glioma (62) liver (28) medulloblastoma
Slide 17: Research Portfolio and Partnered Programs
Research Portfolio and Partnered Programs 17 NON CONFIDENTIAL
Slide 18: Sutro's Cell Free Design to Deliver Three INDs Over Next Three Years
Sutro’s Cell Free Design to Deliver Three INDs Over Next Three Years Sutro’s cell-free Sutro’s next-generation Sutro’s early-stage ADC platform has come of ADCs mitigate toxicity portfolio has broad age, enabling precise risk and increase dose to potential to deliver three design of ADCs with a impr
Slide 19: Sutro Well-Positioned to Lead Development of Next-Generation ADCs
Sutro Well-Positioned to Lead Development of Next-Generation ADCs Conjugated Antibody MODALITY ADC / ISAC iADC / ADC2 Bispecific ADC TARGET Dual 1. Mono- or Bispecific TAA Targeting Tumor Tumor Tumor Antigen Antigen Antigens Toolkit of Fit-to-Purpose Linker-Payloads • DNA targeting / tubulin targeti
Slide 20: Sutro's Platform Enables Therapeutic Index Improvements of ADCs
Sutro's Platform Enables Therapeutic Index (TI) Improvements of ADCs Maximum Tolerated Dose (MTD) vs. Minimum Effective Dose (MED) MTD ADC Outside MTD ADC Tumor TI TI MED ADC Inside Tumor MED ADC Adapted from Gerber et al, mAbs, 2023 HNSTD – highest non-severely toxic dose 20 NON CONFIDENTIAL
Slide 21: Comparison of Topo1i ADC Platforms (Selected)
Comparison of Topo1i ADC Platforms (Selected) Beta-Glu ADC2/ iADC/ Site HT DAR>8 Fc Silent Bispecific Linker Dual LPs iSAC Specific Screening Abbvie AstraZeneca Daiichi Sankyo Dualitybio Genequantum Genmab Gilead Hansoh Hengrui Kelun Lilly Medilink Merck KGaA Pfizer LP – linker payloads; iSAC – immu
Slide 22: STRO-004: DAR8 Exatecan Payload ADC Designed for Enhanced Stability, Potency and Tumor Selectivity
STRO-004: DAR8 Exatecan Payload ADC Designed for Enhanced Stability, Potency and Tumor Selectivity Potent exatecan topo1 inhibitor β-glucuronidase upregulated in tumor Hydrophilic design for optimal PK Enhanced therapeutic window 1000 TAb 100 ADC Conc. [mg/mL] 10 Exatecan MTD ADC 1 0.1 MTD ADC 0.01
Slide 23: STRO-004 DAR8 Exatecan Achieves Sustained Tumor Regressions in Xenograft Models
STRO-004 DAR8 Exatecan Achieves Sustained Tumor Regressions in Xenograft Models of NSCLC and HNSCC at Low Doses Lung (TF+++) Head and Neck (TF++) H1975 Growth Curves Detroit562 Growth Curves 1500 1500 (mm3)3) (mm33)) 1250 1250 Volume(mm volume(mm 1000 1000 Tumor Volume TumorVolume 750 750 500 500 Tu
Slide 24: STRO-004 Widens the Therapeutic Window Compared to First Generation TF ADCs
STRO-004 Widens the Therapeutic Window Compared to First Generation TF ADCs Increased Tolerability Leads to Enhanced Drug Exposure Cmax AUClast MTD ADC 170,880 MTD ADC 1,350 TI TI ADC (h*ug/mL) ADC (ug/mL) MED ADC 50x MED ADC TF-MMAE STRO-004 81.1 HNSTD ~ 5 mg/kg* HNSTD ~ 50 mg/kg # 3,440 STR0-004 A
Slide 25: STRO-004 is a Next Generation ADC with Enhanced Therapeutic Potential
STRO-004 is a Next Generation ADC with Enhanced Therapeutic Potential TF presents an opportunity for STRO-004 is optimally designed for pan-tumor targeting broad therapeutic benefit • Clinical validation of TF in cervical cancer, and signs of • Clinically validated payload with potent activity, byst
Slide 26: Our Focused R&D Strategy: Make ADCs Better Inside the Tumor with Dual-Payloads
Our Focused R&D Strategy: Make ADCs Better Inside the Tumor with Dual-Payloads Multiple different dual-payload ADCs Best-in-class platform potential to optimize dual-payload ADCs Overcome resistance in clinic 26 NON CONFIDENTIAL
Slide 27: Improved In Vitro Activity of Dual-Payload ADC
100 100 100 Improved In Vitro Activity of Dual-Payload ADC % viability % viability % viability 50 50 50 SKBR3 HCC1954 0 KPL4 0 HCC1419 0 0.001 0.01 0.1 1 10 100 1000 0.001 0.01 0.1 1 10 100 1000 0.001 0. nM nM SKBR3 SKBR3SKBR3 HCC1954 HCC1954 HCC1954 KPL4 KPL4 KPL4 NCIN87 HCC1419 150 150 150 150 150
Slide 28: Dual-Payload Topo1i + PARPi ADC Shows Increased Activity Compared to Topo1i ADC
Dual-Payload Topo1i + PARPi ADC Shows Increased Activity Compared to Topo1i ADC MC38-hTF MC38-hTF in vitro potency in vivo anti-tumor activity DAR2 PARPi ADC Vehicle (PBS) DAR4 Topo1i ADC 5 mg/kg DAR4 Topo1i ADC DAR4 Topo1i + DAR2 PARPi ADC2 5 mg/kg DAR4 Topo1i + DAR2 PARPi ADC2 PBS – phosphate buff
Slide 29: Exclusive Global Licensing Agreement with Ipsen for STRO-003 ROR1 Exatecan ADC
Exclusive Global Licensing Agreement with Ipsen for STRO-003 ROR1 Exatecan ADC Licensing Agreement Details Novel, Conjugation Site-Optimized ROR1 ADC Effective April 2024 • Ipsen secures exclusive global rights for development and ROR1 commercialization of STRO-003 • ~$90M in potential near-term pay
Slide 30: New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC)
New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC) Strategic iADC Collaboration • Combining a cytotoxin and immune modulator enabled by Sutro’s dual drug conjugation technology • Sutro has option to share costs/profits for U.S. product development • Sutro retained option
Slide 31: Novel Mechanism of Action Differentiates iADC from Other Immunotherapies
Novel Mechanism of Action Differentiates iADC from Other Immunotherapies Sutro iADCs bridge innate and adaptive immunity to provide broad Sutro STING / PD-1 / CAR-T protection in a single molecule ISAC Vaccine iADC TLR PDL-1 Cells Molecule Targeted and Chemo Mixed ADC Ab Biologic Biologic homogeneou
Slide 32: iADC Offers A New Treatment Option
iADC Offers A New Treatment Option 1 2 3 Potential to work Potential to Has the potential in alone by pushing on synergize with other hard-to-treat cancers the gas of the immune immune therapies by activating an anti- system and priming that release the brake tumor immune new populations of off the
Slide 33: Express Cell-free Platform - Commercial GMP Scale Enabled in 2024
33 Express Cell-free Platform - Commercial GMP Scale Enabled in 2024 Approach / Feature Advantages Results • Stockpiled cell-free extract used to create a Cell-free extract and platform wide variety of proteins elements produced separately • Eliminates cell line development and cell Fully folded, ac
Slide 34: Well Capitalized with Strong Business Development Track Record
34 Well Capitalized with Strong Business Development Track Record ~$426M (1) in cash, cash equivalents & marketable securities and Vaxcyte common stock ~0.7M shares of ~$970M (2) Vaxcyte Funding generated from our (Nasdaq: PCVX) Jun 30, 2024 value collaborators included in above $ amount 1. Based on
Slide 35: Potential for Broad Patients Benefits with Significant Upcoming Milestones
Potential for Broad Patients Benefits with Significant Upcoming Milestones WORLDWIDE OR PHASE 3/ GEOGRAPHIC PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL PARTNER SUTRO-LED PROGRAMS Ovarian Cancer Ovarian Cancer Luveltamab (bevacizumab combo) (Greater Chin
Slide 36: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Anne Borgman, MD Barbara Leyman, PhD Ed Albini, MBA Chief Executive Officer and Chief Medical Officer Chief Business Development Officer Chief Financial Officer Member of the Board of Directors Hans-Peter Gerber, PhD Jane Chung, RPh Linda Fitzpatrick Ve
Sutro Biopharma — Investor Presentation (October 2024) on 6ix